This may be because the external administration of anti-PD-1 antibodies may not be effective in patients with cancers that have progressed to advanced stages under the continuous presence of anti-PD-1 AAb, because these autoantibodies may antagonize the external anti-PD-L1 agents or downregulate the PD-1-associated signaling pathway. The gene discussed is CD274; the disease is cancer.